You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Once-Weekly Basal Insulins: What We Know So Far

  • Authors: Kamlesh Khunti, MD, PhD; Andreas Liebl, MD; Roopa Mehta, PhD, FRCP
  • CME Released: 10/31/2022
  • Valid for credit through: 10/31/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US and non-UK diabetologists and endocrinologists, primary care physicians, and cardiologists.

The goal of this activity is that learners will be better able to understand the role of basal insulin in T2D management, address barriers to its initiation, and have increased awareness of novel once-weekly basal insulin formulations.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current guideline recommendations for the use of basal insulin in patients with T2D
    • Emerging clinical data on novel once-weekly basal insulin formulations
    • Practical strategies on how to overcome obstacles to optimizing insulin therapy in appropriate patients with T2D


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Kamlesh Khunti, MD, PhD

    Professor
    Primary Care Diabetes and Vascular Medicine
    Diabetes Research Centre
    College of Life Sciences
    University of Leicester
    Leicester Diabetes Centre
    Leicester General Hospital
    Leicester, United Kingdom

    Disclosures

    Kamlesh Khunti, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Abbott; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer; Berlin-Chemie AG/Menarini Group; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme GmbH; Napp Pharmaceuticals Limited; Novartis; Novo Nordisk; Roche; Sanofi-Aventis; Servier
    Speaker or member of speakers bureau for: Abbott; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer; Berlin-Chemie AG/Menarini Group; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme GmbH; Napp Pharmaceuticals Limited; Novartis; Novo Nordisk; Roche; Sanofi-Aventis; Servier
    Research funding from: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; Merck Sharp & Dohme GmbH; Novartis; Novo Nordisk; Sanofi-Aventis; Servier

  • Andreas Liebl, MD

    Medical Director
    Center for Diabetes and Metabolism
    Fachklinik Bad Heilbrunn
    Bad Heilbrunn, Germany

    Disclosures

    Andreas Liebl, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; Novo Nordisk; Sanofi
    Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer; Becton, Dickinson and Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Dexcom, Inc.; esanum; Lilly; Medtronic, Inc.; Merck Sharp & Dohme GmbH; Novo Nordisk; OmniaMed; Roche; Sanofi; Seqirus

  • Roopa Mehta, PhD, FRCP

    Endocrinologist and Researcher
    Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
    Mexico City, Mexico

    Disclosures

    Roopa Mehta, PhD, FRCP, has the following relevant financial relationships:
    Consultant or advisor for: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Sanofi
    Speaker or member of speakers bureau for: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Sanofi

Editor

  • Rita Moreira Da Silva, PhD, PharmD

    Medical Education Director, Medscape, LLC

    Disclosures

    Rita Moreira Da Silva, PhD, PharmD, has no relevant financial relationships.

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s )™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Once-Weekly Basal Insulins: What We Know So Far

Authors: Kamlesh Khunti, MD, PhD; Andreas Liebl, MD; Roopa Mehta, PhD, FRCPFaculty and Disclosures

CME Released: 10/31/2022

Valid for credit through: 10/31/2023

processing....

  • Print